2x Icon Desktop

Patients apply as a thin layer,

twice daily to affected skin on up to 20% BSA (no more than 60 g per week)

Directly applied on mild to moderate AD lesions,

including in sensitive skin areas

Rx Pad
For illustrative purposes only.

For topical use only. Not for ophthalmic, oral, or intravaginal use. Stop using when signs and symptoms (eg, itch, rash, and redness) of AD resolve. If signs and symptoms do not improve within 8 weeks, patients should be reexamined by their healthcare provider.

See which of your patients might benefit from OPZELURA >

AD=atopic dermatitis; BID=twice daily; BSA=body surface area.

Reference: 1. Opzelura. Prescribing Information. Incyte Corporation; 2021.